4.93 USD
-0.12 (-2.38%)
4.87 USD
-0.06 (-1.22%)
RADX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 525 industry peers in the Biotechnology industry. The financial health of RADX is average, but there are quite some concerns on its profitability. RADX is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
- RADX had negative earnings in the past year.
- In the past year RADX has reported a negative cash flow from operations.
- RADX had negative earnings in each of the past 5 years.
- In the past 5 years RADX always reported negative operating cash flow.
1.2 Ratios
- The Return On Assets of RADX (-44.34%) is comparable to the rest of the industry.
- The Return On Equity of RADX (-85.60%) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -44.34% | ||
| ROE | -85.6% | ||
| ROIC | N/A |
ROA(3y)-52.36%
ROA(5y)-329.25%
ROE(3y)-111.36%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Gross Margin of RADX (1.08%) is better than 71.62% of its industry peers.
- RADX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 1.08% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- RADX does not have a ROIC to compare to the WACC, probably because it is not profitable.
- RADX has more shares outstanding than it did 1 year ago.
- RADX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- RADX has an Altman-Z score of -2.22. This is a bad value and indicates that RADX is not financially healthy and even has some risk of bankruptcy.
- With a Altman-Z score value of -2.22, RADX perfoms like the industry average, outperforming 49.14% of the companies in the same industry.
- RADX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.22 |
ROIC/WACCN/A
WACC9.36%
2.3 Liquidity
- A Current Ratio of 2.67 indicates that RADX has no problem at all paying its short term obligations.
- The Current ratio of RADX (2.67) is worse than 68.57% of its industry peers.
- A Quick Ratio of 2.67 indicates that RADX has no problem at all paying its short term obligations.
- RADX has a worse Quick ratio (2.67) than 66.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.67 | ||
| Quick Ratio | 2.67 |
3. Growth
3.1 Past
- RADX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 85.80%, which is quite impressive.
- The Revenue has grown by 1114.41% in the past year. This is a very strong growth!
EPS 1Y (TTM)85.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.74%
Revenue 1Y (TTM)1114.41%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%651.94%
3.2 Future
- Based on estimates for the next years, RADX will show a very strong growth in Earnings Per Share. The EPS will grow by 24.83% on average per year.
- RADX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 112.87% yearly.
EPS Next Y-10.26%
EPS Next 2Y1.27%
EPS Next 3Y14.8%
EPS Next 5Y24.83%
Revenue Next Year-100%
Revenue Next 2Y42.8%
Revenue Next 3Y123.94%
Revenue Next 5Y112.87%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
- RADX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Also next year RADX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A more expensive valuation may be justified as RADX's earnings are expected to grow with 14.80% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y1.27%
EPS Next 3Y14.8%
5. Dividend
5.1 Amount
- No dividends for RADX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
RADIOPHARM THERANOSTICS LTD / RADX FAQ
Can you provide the ChartMill fundamental rating for RADIOPHARM THERANOSTICS LTD?
ChartMill assigns a fundamental rating of 3 / 10 to RADX.
What is the valuation status for RADX stock?
ChartMill assigns a valuation rating of 0 / 10 to RADIOPHARM THERANOSTICS LTD (RADX). This can be considered as Overvalued.
Can you provide the profitability details for RADIOPHARM THERANOSTICS LTD?
RADIOPHARM THERANOSTICS LTD (RADX) has a profitability rating of 1 / 10.
How financially healthy is RADIOPHARM THERANOSTICS LTD?
The financial health rating of RADIOPHARM THERANOSTICS LTD (RADX) is 6 / 10.